Immunohistochemistry with IDH1 R132H mutant-specific antibodies is used as an alternative procedure for glioma classification, being particularly useful when direct sequencing cannot be implemented for economic or facility reasons or because of tissue resource limitations [2,7,9,14]. Here, IDH1 is linked to central nervous system cancer.